Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Study Summary

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.